Literature DB >> 30198563

The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions.

Malcolm G Munro1,2, Hilary O D Critchley3, Ian S Fraser4.   

Abstract

BACKGROUND: The International Federation of Gynecology and Obstetrics (FIGO) systems for nomenclature of symptoms of normal and abnormal uterine bleeding (AUB) in the reproductive years (FIGO AUB System 1) and for classification of causes of AUB (FIGO AUB System 2; PALM-COEIN) were first published together in 2011. The purpose was to harmonize the definitions of normal and abnormal bleeding symptoms and to classify and subclassify underlying potential causes of AUB in the reproductive years to facilitate research, education, and clinical care. The systems were designed to be flexible and to be periodically reviewed and modified as appropriate.
OBJECTIVES: To review, clarify, and, where appropriate, revise the previously published systems. METHODOLOGY AND OUTCOME: To a large extent, the process has been an iterative one involving the FIGO Menstrual Disorders Committee, as well as a number of invited contributions from epidemiologists, gynecologists, and other experts in the field from around the world between 2012 and 2017. Face-to-face meetings have been held in Rome, Vancouver, and Singapore, and have been augmented by a number of teleconferences and other communications designed to evaluate various aspects of the systems. Where substantial change was considered, anonymous voting, in some instances using a modified RAND Delphi technique, was utilized.
© 2018 International Federation of Gynecology and Obstetrics.

Entities:  

Keywords:  Abnormal uterine bleeding; Adenomyosis; Anovulatory bleeding; Arteriovenous malformation; Coagulopathy; Endometrial hyperplasia; Endometrial polyp; FIGO; Heavy menstrual bleeding; Heavy uterine bleeding; Intermenstrual bleeding; Irregular menstrual bleeding; Irregular uterine bleeding; Isthmocele; Leiomyoma; Menorrhagia; Metrorrhagia; PALM-COEIN

Mesh:

Year:  2018        PMID: 30198563     DOI: 10.1002/ijgo.12666

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  63 in total

1.  Magnitude and associated factors of menstrual irregularity among undergraduate students of Debre Berhan University, Ethiopia.

Authors:  Abayneh Birlie Zeru; Enguday Demeke Gebeyaw; Esubalew Tesfahun Ayele
Journal:  Reprod Health       Date:  2021-05-21       Impact factor: 3.223

2.  Impact of intramural non-cavity-distorting leiomyoma on placental histopathology and perinatal outcome in singleton live births resulting from in vitro fertilization treatment.

Authors:  Alexander Volodarsky-Perel; Tuyet Nhung Ton Nu; Togas Tulandi; William Buckett; Yaron Gil; Alexandre Machado-Gedeon; Yiming Cui; Jonathan Shaul; Michael H Dahan
Journal:  J Assist Reprod Genet       Date:  2020-06-23       Impact factor: 3.412

3.  Uterine extension determined by MRI: a useful parameter for differentiating subserosal leiomyomas from ovarian tumors.

Authors:  Masaya Kawaguchi; Hiroki Kato; Yoshifumi Noda; Tatsuro Furui; Ken-Ichirou Morishige; Fuminori Hyodo; Masayuki Matsuo
Journal:  Abdom Radiol (NY)       Date:  2022-01-07

4.  Hyperprolactinemia as a prognostic factor for menstrual disorders in female adolescents with advanced chronic kidney disease.

Authors:  Juana Serret-Montaya; Jessie N Zurita-Cruz; Miguel A Villasís-Keever; Alejandra Aguilar-Kitsu; Claudia Del Carmen Zepeda-Martinez; Irving Cruz-Anleu; Beatriz C Hernández-Hernández; Sara R Alonso-Flores; Leticia Manuel-Apolinar; Leticia Damasio-Santana; Abigail Hernandez-Cabezza; José C Romo-Vázquez
Journal:  Pediatr Nephrol       Date:  2020-02-10       Impact factor: 3.714

5.  Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.

Authors:  Ayman Al-Hendy; Andrea S Lukes; Alfred N Poindexter; Roberta Venturella; Claudio Villarroel; Hilary O D Critchley; Yulan Li; Laura McKain; Juan C Arjona Ferreira; Andria G M Langenberg; Rachel B Wagman; Elizabeth A Stewart
Journal:  N Engl J Med       Date:  2021-02-18       Impact factor: 91.245

6.  Clinical Manifestations of Polycystic Ovary Syndrome and Associations With the Vaginal Microbiome: A Cross-Sectional Based Exploratory Study.

Authors:  Xiang Hong; Pengfei Qin; Jiechen Yin; Yong Shi; Yan Xuan; Zhengqi Chen; Xu Zhou; Hong Yu; Danhong Peng; Bei Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-23       Impact factor: 5.555

7.  Association of severity of menstrual dysfunction with hyperinsulinemia and dysglycemia in polycystic ovary syndrome.

Authors:  U Ezeh; M D Pisarska; R Azziz
Journal:  Hum Reprod       Date:  2022-03-01       Impact factor: 6.918

8.  Challenges and future directions in menstrual cycle research.

Authors:  Anne Marie Jukic
Journal:  Paediatr Perinat Epidemiol       Date:  2020-03-12       Impact factor: 3.103

Review 9.  Uterine Fibroids and Pregnancy: How Do They Affect Each Other?

Authors:  Larissa M Coutinho; Wiviane A Assis; Ananda Spagnuolo-Souza; Fernando M Reis
Journal:  Reprod Sci       Date:  2021-06-17       Impact factor: 2.924

10.  Angiotensin-converting enzyme 2, the SARS-CoV-2 cellular receptor, is widely expressed in human myometrium and uterine leiomyoma.

Authors:  Alexon M Racilan; Wiviane A Assis; Maíra Casalechi; Ananda Spagnolo-Souza; Marcelo A Pascoal-Xavier; Ana C Simões-E-Silva; Helen L Del Puerto; Fernando M Reis
Journal:  J Endometr Pelvic Pain Disord       Date:  2021-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.